About BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BCRX
CUSIP09058V10
Phone919-859-1302
Debt
Debt-to-Equity Ratio0.23%
Current Ratio1.68%
Quick Ratio1.68%
Price-To-Earnings
Trailing P/E Ratio-6.24
Forward P/E Ratio-6.16
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.19 million
Price / Sales19.08
Cash FlowN/A
Price / CashN/A
Book Value$0.85 per share
Price / Book5.73
Profitability
EPS (Most Recent Fiscal Year)($0.78)
Net Income$-65,780,000.00
Net Margins-261.18%
Return on Equity-106.53%
Return on Assets-42.94%
Miscellaneous
Employees85
Outstanding Shares98,700,000
BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions
What is BioCryst Pharmaceuticals' stock symbol?
BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."
How were BioCryst Pharmaceuticals' earnings last quarter?
BioCryst Pharmaceuticals (NASDAQ:BCRX) released its earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. The biotechnology company had revenue of $3.89 million for the quarter, compared to analysts' expectations of $6.07 million. BioCryst Pharmaceuticals had a negative return on equity of 106.53% and a negative net margin of 261.18%. The business's revenue for the quarter was down 56.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.06) EPS. View BioCryst Pharmaceuticals' Earnings History.
When is BioCryst Pharmaceuticals' next earnings date?
What price target have analysts set for BCRX?
8 equities research analysts have issued 1 year price objectives for BioCryst Pharmaceuticals' shares. Their predictions range from $6.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $8.8333 in the next twelve months. View Analyst Ratings for BioCryst Pharmaceuticals.
What are Wall Street analysts saying about BioCryst Pharmaceuticals stock?
Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (3/5/2018)
- 2. HC Wainwright analysts commented, "NewCo Combines HAE Commercial & Deal-Making Expertise With Core Competency in Structure-Based Drug Design Diversification and management expertise drive the deal. Biocryst today announced its intention to merge with the oligomer company Idera (IDRA; Buy Rated) to form a NewCo that will continue to develop treatments for both HAE as well as checkpoint-refractory myeloma." (1/23/2018)
- 3. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)
Are investors shorting BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals saw a drop in short interest in the month of March. As of March 15th, there was short interest totalling 11,058,975 shares, a drop of 8.2% from the February 28th total of 12,044,486 shares. Based on an average daily trading volume, of 966,749 shares, the short-interest ratio is presently 11.4 days. Currently, 11.4% of the shares of the stock are short sold.
Who are some of BioCryst Pharmaceuticals' key competitors?
Some companies that are related to BioCryst Pharmaceuticals include Denali Therapeutics (DNLI), Repligen (RGEN), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), Cellectis (CLLS), REGENXBIO (RGNX), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR) and Bavarian Nordic (BVNRY).
Who are BioCryst Pharmaceuticals' key executives?
BioCryst Pharmaceuticals' management team includes the folowing people:
- Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 57)
- Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 50)
- Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 63)
- Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 65)
- Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 51)
Has BioCryst Pharmaceuticals been receiving favorable news coverage?
Media stories about BCRX stock have been trending positive this week, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioCryst Pharmaceuticals earned a news impact score of 0.27 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.74 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are BioCryst Pharmaceuticals' major shareholders?
BioCryst Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include
GREAT POINT PARTNERS LLC
(7.60%),
GREAT POINT PARTNERS LLC
(7.60%), RA CAPITAL MANAGEMENT, LLC (7.10%) and RA CAPITAL MANAGEMENT, LLC (7.10%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Bros Advisors Lp Baker, Fred E Cohen, Thomas R Staab II, William P Sheridan and Yarlagadda S Babu. View Institutional Ownership Trends for BioCryst Pharmaceuticals.
How do I buy shares of BioCryst Pharmaceuticals?
Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioCryst Pharmaceuticals' stock price today?
One share of BCRX stock can currently be purchased for approximately $4.87.
How big of a company is BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals has a market capitalization of $479.69 million and generates $25.19 million in revenue each year. The biotechnology company earns $-65,780,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. BioCryst Pharmaceuticals employs 85 workers across the globe.
How can I contact BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]
MarketBeat Community Rating for BioCryst Pharmaceuticals (BCRX)
MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for BioCryst Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.8333, suggesting that the stock has a possible upside of 81.38%. The high price target for BCRX is $15.00 and the low price target for BCRX is $6.00. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.63 | 2.63 | 2.67 | 2.70 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.8333 | $8.8333 | $9.1429 | $9.25 |
| Price Target Upside: | 81.38% upside | 66.04% upside | 71.86% upside | 79.26% upside |
BioCryst Pharmaceuticals (NASDAQ:BCRX) Consensus Price Target History
BioCryst Pharmaceuticals (NASDAQ:BCRX) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
BioCryst Pharmaceuticals (NASDAQ:BCRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
BioCryst Pharmaceuticals (NASDAQ BCRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 91.45%
BioCryst Pharmaceuticals (NASDAQ BCRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/13/2017 | William P Sheridan | CMO | Sell | 64,310 | $4.72 | $303,543.20 | |  |
| 9/18/2017 | Fred E Cohen | Director | Sell | 54,250 | $5.42 | $294,035.00 | 173,660 | |
| 3/20/2017 | Thomas R Staab II | CFO | Sell | 3,250 | $9.20 | $29,900.00 | 144,710 | |
| 3/10/2017 | Thomas R Staab II | Insider | Sell | 3,250 | $9.06 | $29,445.00 | 120,563 | |
| 3/8/2017 | Thomas R Staab II | Insider | Sell | 6,500 | $8.43 | $54,795.00 | 123,813 | |
| 3/6/2017 | Thomas R Staab II | Insider | Sell | 3,250 | $7.90 | $25,675.00 | 120,563 | |
| 12/19/2016 | Thomas R Staab II | Insider | Sell | 3,250 | $7.45 | $24,212.50 | 127,437 | |
| 9/14/2016 | Alane P Barnes | VP | Sell | 8,357 | $4.27 | $35,684.39 | 79,377 | |
| 8/25/2016 | Yarlagadda S Babu | VP | Sell | 30,000 | $4.06 | $121,800.00 | 111,428 | |
| 8/16/2016 | Bros. Advisors Lp Baker | Major Shareholder | Sell | 4,046,590 | $5.00 | $20,232,950.00 | | |
| 8/12/2016 | Thomas R Staab II | Insider | Sell | 5,864 | $5.18 | $30,375.52 | 128,745 | |
| 8/9/2016 | Thomas R Staab II | Insider | Sell | 14,577 | $4.43 | $64,576.11 | 130,051 | |
| 1/28/2016 | Bros. Advisors Lp Baker | major shareholder | Buy | 88,345 | $6.95 | $613,997.75 | 23,459 | |
| 1/22/2016 | Bros. Advisors Lp Baker | major shareholder | Buy | 106,800 | $7.28 | $777,504.00 | 23,459 | |
| 1/20/2016 | Bros. Advisors Lp Baker | major shareholder | Buy | 52,695 | $6.87 | $362,014.65 | 23,459 | |
| 1/19/2016 | Bros. Advisors Lp Baker | major shareholder | Buy | 92,200 | $7.12 | $656,464.00 | 23,459 | |
| 1/15/2016 | Bros. Advisors Lp Baker | major shareholder | Buy | 200,000 | $7.46 | $1,492,000.00 | 23,459 | |
| 12/21/2015 | Thomas R Staab II | CFO | Sell | 3,052 | $10.86 | $33,144.72 | 136,592 | |
| 12/17/2015 | Thomas R Staab II | CFO | Sell | 3,000 | $10.49 | $31,470.00 | 139,644 | |
| 7/20/2015 | Thomas R Staab II | CFO | Sell | 3,500 | $16.50 | $57,750.00 | | |
| 6/22/2015 | Thomas R Staab II | CFO | Sell | 3,750 | $16.00 | $60,000.00 | | |
| 6/19/2015 | Alane P Barnes | VP | Sell | 3,000 | $15.00 | $45,000.00 | | |
| 6/19/2015 | Jon P Stonehouse | CEO | Sell | 20,000 | $15.02 | $300,400.00 | | |
| 6/19/2015 | Thomas R Staab II | CFO | Sell | 16,375 | $14.36 | $235,145.00 | | |
| 6/19/2015 | William P Sheridan | CMO | Sell | 70,389 | $15.05 | $1,059,354.45 | | |
| 6/5/2015 | Thomas R Staab II | CFO | Sell | 6,000 | $12.75 | $76,500.00 | | |
| 5/18/2015 | Thomas R Staab II | CFO | Sell | 3,000 | $11.00 | $33,000.00 | | |
| 3/19/2015 | Yarlagadda S Babu | VP | Sell | 12,105 | $10.16 | $122,986.80 | | |
| 3/5/2015 | Yarlagadda S Babu | VP | Sell | 37,400 | $10.59 | $396,066.00 | | |
| 3/4/2015 | Yarlagadda S Babu | VP | Sell | 10,495 | $10.50 | $110,197.50 | | |
| 2/20/2015 | Nancy J Hutson | Director | Buy | 10,000 | $10.27 | $102,700.00 | | |
| 12/30/2014 | William P Sheridan | CMO | Sell | 128,399 | $12.36 | $1,587,011.64 | | |
| 12/29/2014 | Thomas R Staab II | CFO | Sell | 9,500 | $12.56 | $119,320.00 | | |
| 12/29/2014 | William P Sheridan | CMO | Sell | 105,295 | $12.43 | $1,308,816.85 | | |
| 8/27/2014 | Thomas R Staab II | CFO | Sell | 10,000 | $13.58 | $135,800.00 | | |
| 7/1/2014 | Thomas R Staab II | CFO | Sell | 3,125 | $13.00 | $40,625.00 | | |
| 6/23/2014 | Thomas R Staab II | CFO | Sell | 3,125 | $12.49 | $39,031.25 | | |
| 6/17/2014 | Thomas R Staab II | CFO | Sell | 3,125 | $12.00 | $37,500.00 | | |
| 3/14/2014 | Thomas Staab II | CFO | Sell | 3,125 | $11.24 | $35,125.00 | 126,616 | |
| 3/6/2014 | Kenneth Lee, Jr. | Director | Sell | 12,665 | $12.69 | $160,718.85 | 10,252 | |
| 11/12/2013 | George Abercrombie | Director | Buy | 3,000 | $6.19 | $18,570.00 | 6,000 | |
| 8/1/2013 | Felix Baker | Major Shareholder | Buy | 1,136,364 | $4.40 | $5,000,001.60 | | |
| 3/5/2013 | George B Abercrombie | Director | Buy | 3,000 | $1.23 | $3,690.00 | | |
| 12/14/2012 | Peder Jensen | Director | Buy | 20,000 | $1.51 | $30,200.00 | | |
(Data available from 1/1/2013 forward)
BioCryst Pharmaceuticals (NASDAQ BCRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | BioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 5:46 AM |
| BioCryst Pharmaceuticals (BCRX) Expected to Post Quarterly Sales of $10.20 Million
www.americanbankingnews.com - April 21 at 3:50 AM |
| -$0.16 Earnings Per Share Expected for BioCryst Pharmaceuticals (BCRX) This Quarter
www.americanbankingnews.com - April 19 at 1:18 PM |
| Contrasting Voyager Therapeutics (VYGR) and BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - April 18 at 5:15 PM |
| BioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 15 at 1:40 PM |
| BioCryst Pharmaceuticals (BCRX) Upgraded at BidaskClub
www.americanbankingnews.com - April 14 at 6:22 PM |
| BioCryst Pharmaceuticals (BCRX) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - April 12 at 12:29 AM |
| Noble Financial Reiterates "Buy" Rating for BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - April 11 at 8:27 PM |
| ValuEngine Lowers BioCryst Pharmaceuticals (BCRX) to Sell
www.americanbankingnews.com - April 11 at 3:58 PM |
 | BioCryst and Idera postpone shareholder meetings for merger vote until July 10
seekingalpha.com - April 10 at 8:26 AM |
| Brokerages Anticipate BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $10.20 Million
www.americanbankingnews.com - April 4 at 2:50 AM |
| -$0.16 EPS Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter
www.americanbankingnews.com - April 2 at 1:15 PM |
| HC Wainwright Reiterates Buy Rating for BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - April 1 at 10:34 AM |
| BioCryst Pharmaceuticals (BCRX) Raised to "Outperform" at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 12:54 PM |
| Short Interest in BioCryst Pharmaceuticals, Inc. (BCRX) Drops By 8.2%
www.americanbankingnews.com - March 30 at 2:26 AM |
 | Edited Transcript of BCRX earnings conference call or presentation 27-Feb-18 4:00pm GMT
finance.yahoo.com - March 29 at 8:27 AM |
 | Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals, Inc. (BCRX)
feeds.benzinga.com - March 24 at 1:48 AM |
 | BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 23 at 8:18 AM |
| BioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 1:40 PM |
| BioCryst Pharmaceuticals (BCRX) and Pharming Group (PHGUF) Head to Head Contrast
www.americanbankingnews.com - March 18 at 5:18 PM |
| $10.20 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter
www.americanbankingnews.com - March 18 at 5:57 AM |
| Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) to Announce -$0.16 EPS
www.americanbankingnews.com - March 16 at 11:42 AM |
 | BioCryst Pharma (BCRX) Reports Initiation of Phase 3 APeX-2 Trial of BCX7353 - StreetInsider.com
www.streetinsider.com - March 15 at 8:16 AM |
| BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
finance.yahoo.com - March 15 at 8:16 AM |
| Blog Exposure - Esperion Therapeutics Reported Positive Top-line Results from First Pivotal Phase-3 Study of its Cholestrol Drug, Bempedoic Acid
finance.yahoo.com - March 9 at 8:20 AM |
| BioCryst Pharmaceuticals, Inc. (BCRX) Holdings Trimmed by VHCP Management II LLC
www.americanbankingnews.com - March 6 at 10:50 AM |
| BioCryst Pharmaceuticals (BCRX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 5 at 6:12 PM |
| Q1 2018 Earnings Estimate for BioCryst Pharmaceuticals, Inc. Issued By Jefferies Group (BCRX)
www.americanbankingnews.com - March 5 at 2:56 AM |
| Emory University Has $1.88 Million Position in BioCryst Pharmaceuticals, Inc. (BCRX)
www.americanbankingnews.com - March 4 at 2:59 PM |
| Analysts Offer Predictions for BioCryst Pharmaceuticals, Inc.'s FY2022 Earnings (BCRX)
www.americanbankingnews.com - March 2 at 5:32 PM |
| BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q4 ... - Seeking Alpha
seekingalpha.com - February 28 at 8:17 AM |
| BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema
finance.yahoo.com - February 28 at 8:17 AM |
| BioCryst Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 27 at 5:55 PM |
| Does BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) Earnings Growth Make It An Outperformer?
finance.yahoo.com - February 27 at 5:55 PM |
| BioCryst Pharmaceuticals (BCRX) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - February 27 at 11:31 AM |
| BioCryst Pharmaceuticals misses by $0.05, misses on revenue
seekingalpha.com - February 27 at 8:37 AM |
| BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in ... - GlobeNewswire (press release)
www.globenewswire.com - February 27 at 8:18 AM |
| Analysis: Positioning to Benefit within Healthcare Services Group, Oshkosh, PICO, Chicago Rivet & Machine, Ashland Global, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - February 27 at 8:18 AM |
| BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger
finance.yahoo.com - February 27 at 8:18 AM |
| Options Traders Expect Huge Moves in BioCryst (BCRX) Stock
finance.yahoo.com - February 26 at 5:45 PM |
 | Why significant BioCryst shareholder plans to vote against Idera merger - Triangle Business Journal
www.bizjournals.com - February 21 at 8:21 AM |
| BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences - GlobeNewswire (press release)
globenewswire.com - February 20 at 8:16 AM |
| BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
feeds.benzinga.com - February 19 at 2:31 PM |
| Contrasting Tobira Development (TBRA) & BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - February 19 at 1:20 PM |
| BioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 19 at 4:10 AM |
 | Great Point Partners, LLC Opposes The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc. - PR Newswire (press release)
www.prnewswire.com - February 17 at 8:13 AM |
| BioCryst Pharmaceuticals (BCRX) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - February 14 at 11:42 PM |
| BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Post Quarterly Sales of $6.63 Million
www.americanbankingnews.com - February 12 at 4:30 AM |
| BioCryst Pharmaceuticals (BCRX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 11 at 10:16 PM |
| BioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 30 at 1:32 PM |
BioCryst Pharmaceuticals (NASDAQ:BCRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
BioCryst Pharmaceuticals (NASDAQ:BCRX) Income Statement, Balance Sheet and Cash Flow Statement
BioCryst Pharmaceuticals (NASDAQ BCRX) Stock Chart for Thursday, April, 26, 2018
Loading chart…
